These multifaceted changes result in a highly immunosuppressive TME that facilitates tumor growth, enables evasion of immune-mediated destruction, and may contribute to plasticity and resistance to therapies targeting the AR and other key pathways in prostate cancer. This evidence concerns the gene AR and prostate carcinoma.